First Nasal Vaccine Developed by Bharat Biotech supported by DBT-BIRAC gets the nod of regulator for Phase 2/3 Trial
THE VOICE OF CHANDIGARH NEWS:
The Department of Biotechnology (DBT) and its PSU, Biotechnology Industry Research Assistance Council (BIRAC) have been at the forefront in the fight against the prevailing global crisis. They together have strategized to fast-track R & D efforts especially for vaccine development, diagnostics, drug repurposing, therapeutics and testing. The development of vaccines has been the top priority of the Department of Biotechnology.
This Mission COVID Suraksha was launched to reinforce and accelerate COVID-19 vaccine development efforts as part of the third stimulus package, Atmanirbhar 3.0. The focus of this mission is to consolidate and streamline available resources towards a warpath for accelerated vaccine development in order tobring a safe, efficacious, affordable and accessible COVID-19 Vaccine to the citizens at the earliest with a focus on Atmanirbhar Bharat.
Bharat Biotech’s intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials. This is the first of its kind COVID-19 jab to undergo human clinical trials in India. BBV154 is an intranasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine.BBIL has in-licensed technology from Washington University in St Louis, USA.
Phase 1 Clinical trial has been completed in age groups ranging ≥18 to ≤60 years. The Company reports that the doses of the vaccine administered to healthy volunteers in the Phase I clinical trial, has been well tolerated. No serious adverse events reported. Previously, the vaccine was found to be safe, immunogenic and well tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit high level of neutralizing antibodies in animal studies.
The regulatory approval has been receivedfor conducting“A Phase 2 randomized, multi-centric, Clinical Trial of Heterologus Prime-Boost Combination of SARS-CoV-2 Vaccines to evaluate the immunogenicity and safety of BBV152 (COVAXIN®) with BBV154 (Adenoviral Intranasal COVID-19 vaccine) in Healthy Volunteers.”
Dr RenuSwarup, Secretary, DBT and Chairperson, BIRAC speaking on the subject said that “the Department through Mission COVID Suraksha, is committed to development of safe and efficacious COVID-19 vaccines. Bharat Biotech’s BBV154 Covid Vaccine is the first intranasal vaccine being developed in the country entering into late-stage clinical trials.”
